1st June 2018
Committee for Medicinal Products for Human Use adopts positive opinion for use of Aimovig in migraine prevention
The European Medicines Agency will now consider this guidance
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Aimovig (erenumab) for the prevention of migraine in adult patients who experience more than four migraine days per month.
If approved, Aimovig will be the first and only preventive treatment designed specifically for migraine that blocks the calcitonin gene-related peptide (CGRP) receptor thought to be responsible for transmitting the pain signals associated with migraine.
The European Medicines Agency will now consider this guidance from the CHMP as it makes its final decision on the marketing authorisation for Aimovig, expected within three months. Aimovig was approved by the U.S. Food and Drug Administration for the prevention of migraine in adults last month.
Responding to the announcement, Wendy Thomas, Chief Executive of The Migraine Trust, said:
“We are delighted as this is an important step in gaining access to this ground-breaking treatment for people who have to deal with the misery of migraine.
“The Migraine Trust was closely associated with the development of erenumab through the recruitment of patients for trials and by supporting research in this area over many years.
“We are hopeful that people in the UK with migraine can soon be able to receive dedicated treatment and a chance of a better quality of life.”